INNOVADERM CRO IS NOW INDERO.

3 Tips on How to Manage Rosacea Trials

Indero

Indero

Team of Experts

Author picture

3 Tips on How to Manage Rosacea Trials

April is dedicated to raising awareness around Rosacea.

One of Innovaderm’s all-star project managers, Nalanie Johnson, shared some tips that are crucial when managing a clinical trial to the complexity of a therapeutic indication such as Rosacea:

1. In managing Rosacea studies, it is important to understand the indication and patient flow. Most patients will come from advertisement instead of the site’s database;

2. Having a central ad campaign as a recruitment strategy is very crucial to achieving the study enrollment milestone;

3. Keep a keen eye on subject drop out rates and encourage sites to keep subjects motivated to complete the study. Patients want to see results fast as they are used to having healthy skin due to the late onset of the disease, therefore they may lack the patience to wait for the study results.

 

Learn more about how we can assist with your next rosacea, medical aesthetics or any other dermatological indication trial.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.